Clinical Pharmacogenomic MT-RNR1 Screening for Aminoglycoside-Induced Ototoxicity and the Post-Test Counseling Conundrum.
Robert RigobelloJay ShawDaniel IlgRebekah S ZimmermanLisa EdelmannRuth KornreichStuart A ScottNeal CodyPublished in: Clinical pharmacology and therapeutics (2023)
Aminoglycoside antibiotic exposure can result in ototoxicity and irreversible hearing loss among individuals that harbor the m.1555A>G variant in the mitochondrial 12S rRNA gene, MT-RNR1. Importantly, pre-emptive m.1555A>G screening has been shown to reduce the prevalence of pediatric aminoglycoside-induced ototoxicity; however, professional guidelines to support and guide post-test pharmacogenomic counseling in this context are not currently available. This Perspective highlights key issues with delivering MT-RNR1 results, including longitudinal familial care considerations and communicating m.1555A>G heteroplasmy.
Keyphrases
- pseudomonas aeruginosa
- high glucose
- diabetic rats
- healthcare
- acinetobacter baumannii
- oxidative stress
- palliative care
- smoking cessation
- mitochondrial dna
- cystic fibrosis
- clinical practice
- drug induced
- hiv testing
- hearing loss
- clinical decision support
- copy number
- early onset
- human immunodeficiency virus
- men who have sex with men
- electronic health record
- cross sectional
- antiretroviral therapy
- dna methylation